In this episode of Everything GLP-1, Dr. Tom Lavin speaks with Scott Brunner, CEO and President of the Alliance for Pharmacy Compounding, to examine how pharmacy compounding has shaped patient access during the GLP-1 shortage era. Rather than framing compounding as a workaround, Brunner explains how it operates within a rigorous, multilayered regulatory system involving the FDA, USP standards, and state boards of pharmacy.

Together, they discuss how drug makers have sometimes conflated legitimate compounding with counterfeit activity, the growing black market for unapproved peptides, and why personalized, prescriber-directed formulations remain essential for patients whose needs fall outside commercially available options. Brunner also outlines the case for creating a regulated pathway for peptide compounding, including enhanced safety data collection.

Listeners will come away with a clearer understanding of how compounding regulation actually works, why it matters for patient safety and access, and what policy changes may be coming. It is a valuable listen for clinicians, healthcare leaders, and anyone following the future of GLP-1 access and obesity medicine.

DISCLAIMER: Dr. Lavin's podcast is for informational and entertainment purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional for any medical concerns or before making decisions about your health.

Hosted on Acast. See acast.com/privacy for more information.